VINC Vincerx Pharma, Inc.
Healthcare$0.01-1.17%ClosedMarket Cap: $66,475
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.03
P/S
0.06
EV/EBITDA
0.37
DCF Value
$0.78
FCF Yield
-15811.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
50.0%
Operating Margin
-1138.6%
Net Margin
-1216.7%
ROE
-542.5%
ROA
-277.3%
ROIC
-588.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-3.3M | $-5.0M | $— | — |
| Q4 null | $1.1M | 50.0% | $-8.8M | $-8.0M | $— | — |
| FY null | $0.00 | NaN% | $-31.5M | $-30.1M | $— | — |
| Q3 null | $0.00 | NaN% | $-7.8M | $-7.8M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-7.4M | $-1.8M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-7.5M | $-12.4M | $— | — |
| Q4 null | $1.3M | 80.4% | $-5.5M | $-5.0M | $— | — |
| FY null | $0.00 | -Infinity% | $-42.6M | $-40.2M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-10.3M | $-9.7M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-11.7M | $-11.2M | $— | — |
| Q1 2023 | $0.00 | -Infinity% | $-15.1M | $-13.6M | $-2.51 | — |
| Q4 2022 | $0.00 | -Infinity% | $-15.4M | $-5.5M | $-2.34 | — |